Wegovy label drops BMI numbers from its weight-loss indications
Wegovy's label now describes the weight-management population in words rather than BMI numbers, a shift recorded as two indications revisions in 2025.
The prescribing information for Wegovy no longer prints a BMI cutoff in the section that describes who the medicine is for [1]. As written now, that section covers adults who have obesity, and adults who have overweight along with at least one weight-related comorbid condition [1].
Two dates appear in the label's own list of major changes for Indications and Usage: 08/2025 and 12/2025 [1]. The DailyMed labeling record reviewed here carries an update date of June 18, 2026 [1]. Wegovy is semaglutide, made by Novo Nordisk, and is sold as a once-weekly injection and as an oral tablet [1].
What each form is cleared for
The injection's indications, used with a reduced-calorie diet and more physical activity, cover three things. The first is lowering the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults who have established cardiovascular disease plus obesity or overweight. The second is losing excess body weight and keeping it off in adults and in children 12 and older who have obesity, and in adults with overweight plus at least one weight-related comorbid condition. The third is treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), the condition formerly called NASH, with moderate to advanced liver fibrosis consistent with stages F2 to F3 in adults [1].
The MASH indication came through accelerated approval, based on improvement in MASH and fibrosis; keeping that approval may depend on a confirmatory trial that verifies clinical benefit [1].
The tablet version carries two indications: the same cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, and weight reduction with long-term maintenance in adults with obesity, or in adults with overweight and at least one weight-related comorbid condition [1].
A limitation of use states that Wegovy tablets or injection should not be combined with another semaglutide product or with any other GLP-1 receptor agonist [1].
Other entries on the label
Beyond the indications text, the change log shows Dosage and Administration updates dated 08/2025, 12/2025 and 03/2026 [1]. A warning about acute kidney injury from volume depletion was added 08/2025, and one about severe gastrointestinal reactions 10/2025 [1]. The warning on suicidal behavior and ideation is marked as removed 02/2026, and a caution against sharing the Wegovy FlexTouch pen between patients is dated 06/2026 [1]. The boxed warning about thyroid C-cell tumors stands, and the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 [1].
Why it matters for patients
Anyone reading the label hoping to match a number to their own situation will not find one in the indications section [1]. That section does not define obesity or overweight with a figure either [1], and it does not say where a numeric cutoff should come from instead. How payers, pharmacy benefit managers or state programs responded to the two revisions has not been reported.
What happens next
Because the MASH use was granted under accelerated approval, follow-up work is expected to verify and describe clinical benefit in a confirmatory trial [1]. The label records no indications revisions past 08/2025 and 12/2025 [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.